Rovithi, Maria <br/><br/>
Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity.  [electronic resource] 

 -  Angiogenesis  08 2017 
 - 287-289 p.  digital 
<br/><br/> Publication Type: Letter; Review 
<br/><br/><label>ISSN: </label>1573-7209 
<br/><br/><label>Standard No.: </label>10.1007/s10456-017-9555-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Humans<br/>Neoplasms--blood supply<br/>Protein-Tyrosine Kinases--therapeutic use